HUNTINGTON, N.Y., April 10, 2024 /PRNewswire/ -- Sen-Jam Pharmaceutical, an innovative life sciences company developing a portfolio of revolutionary anti-inflammatories by repurposing existing molecules for novel uses, has entered a third strategic partnership with KVK-Tech. KVK-Tech is a leading Specialty Pharmaceutical Manufacturing company that will be providing formulation and Chemistry, Manufacturing & Controls (CMC) for Sen-Jam's first injectable anti-inflammatory therapeutic, SJP-100.
LOS ANGELES and HUNTINGTON, N.Y., Sept. 22, 2022 /PRNewswire/ -- People Science™, a direct-to-consumer scientific research company providing a scaled R&D platform for alternative medicines, and Sen-Jam Pharmaceutical, a drug development company creating novel solutions for pain and inflammation, announce today a partnership to develop tools for healthcare providers and their patients to track, monitor, and understand the effects of treatments on their health in the real world setting. Using a data-driven and people-forward approach, People Science will develop protocols and workflows, designed in collaboration with experts in opioid use disorder and inflammatory disease states. People Science's proprietary software technology CHLOE™, the Consumer Health Learning and Organizing Ecosystem, will enable both the healthcare providers and their patients to track symptoms, outcomes, quality of life, and the response to various therapies and approaches. CHLOE is a highly customizable, modular software technology that combines a consumer-facing mobile app with a rigorous high-quality clinical research platform. People Science will then work with engaged clinicians and their patients to prototype the useability and usefulness of this tool in everyday practice in the clinics and at home.
Sen-Jam Pharmaceutical, an innovative life sciences company developing a portfolio of revolutionary anti-inflammatories by repurposing existing...
HUNTINGTON, N.Y., May 6, 2022 /PRNewswire/ -- Sen-Jam Pharmaceutical, an innovative life sciences company developing a portfolio of revolutionary anti-inflammatories by repurposing existing molecules for novel combination therapy, this week began enrolling patients into their Phase 2 Clinical Trial for their promising oral COVID therapeutic. At the same time, the company has joined forces with KVK Tech that will provide access to world-class Formulation and Chemistry, Manufacturing & Controls (CMC) for their COVID-19 therapeutic.
HUNTINGTON, N.Y., March 22, 2022 /PRNewswire/ -- Sen-Jam Pharmaceutical, an innovative life sciences company developing a portfolio of revolutionary anti-inflammatories by repurposing existing molecules for novel combination therapy, has entered a strategic partnership with KVK Tech. KVK Tech is a leading Specialty Pharmaceutical Manufacturing company that will be providing formulation and Chemistry, Manufacturing & Controls (CMC) for their oral COVID-19 therapeutic. They will work in parallel with Sen-Jam teams while they complete their phase II clinical trials to have a finished product in 9-12 months. This clinical trial is another powerhouse partnership between Sen-Jam and Duke-NUS Medical School which has an esteemed group of international researchers working in concert with Sen-Jam's Head of Clinical Development and Founder, Jackie Iversen, RPh, MS.
HUNTINGTON, N.Y., March 16, 2022 /PRNewswire/ -- Since the discovery of alcohol thousands of years ago, drinkers have enjoyed consuming alcoholic beverages but also suffer from the next-day negative effects of alcohol intake. This so-called alcohol hangover is defined as the combination of negative mental and physical symptoms which can be experienced after a single episode of alcohol consumption, starting when blood alcohol concentration (BAC) approaches zero.